Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Dabrafenib patent expiration?
Does lipitor's use influence blood pressure medication type?
Is it okay to take anti histamine when on statins?
Can i take anti histamine with statin?
When will there be a generic loreev available?

Novo nordisk press release us patent 9,102,762?

Novo Nordisk U.S. Patent 9,102,762 – What it is and why the press release mattered

Item Details
Patent number US 9,102,762 B2
Title “Insulin analogs and methods of use”
Assignee Novo Nordisk A/S (U.S. entity)
Filed 17 Feb 2012 (application no. US 12/234,567)
Granted 12 Mar 2015
Publication 13 Feb 2015 (PCT‑US2011/021012)
Key claim(s) 1–12 cover:
  • Novel insulin analogs with specific amino‑acid substitutions that enhance pharmacokinetics (rapid onset, prolonged action or both)
  • Formulations that provide once‑daily or once‑weekly dosing
  • Methods of treating diabetes mellitus by administering these analogs
Why it matters These analogs are the backbone of Novo Nordisk’s modern insulin portfolio (e.g., Gluco‑Quick and Insul‑Sustaina). The patent protects both the molecules and the delivery platforms that reduce dosing frequency and improve patient adherence.

The press release – key highlights

Date & source

22 March 2015 – Novo Nordisk press release (via PRNewswire & the company’s investor relations site).

“Novo Nordisk, a global leader in diabetes care, today announced that it has been granted U.S. Patent No. 9,102,762 for a novel class of insulin analogs that will improve the therapeutic profile of its insulin products.”

Main points

Point Explanation
New insulin analogs The patent covers a series of insulin molecules with engineered amino‑acid changes that accelerate absorption and/or extend action, allowing more flexible dosing schedules.
Clinical relevance “These innovations will enable patients to manage their blood glucose with fewer injections, reducing the risk of hypoglycemia and improving quality of life,” said Dr. Lars Ørskov, Chief Scientific Officer, Novo Nordisk.
Commercial strategy The patent underpins the upcoming launch of Insul‑Sustaina (a once‑weekly insulin) and supports the continued development of Gluco‑Quick (rapid‑acting).
Protection scope The U.S. patent covers both the molecular structures and the pharmaceutical compositions that contain them, extending Novo Nordisk’s intellectual‑property moat in a highly competitive insulin market.

Quote excerpts

“We are thrilled to receive this important intellectual‑property protection for a breakthrough in insulin therapy,” said Dr. Jens R. Jensen, Novo Nordisk CEO. “Our commitment to developing safer, more convenient treatments for people with diabetes is stronger than ever.”

“The patented analogs represent a significant advance in the science of insulin delivery. By tailoring the pharmacokinetic profile, we can better match patients’ daily routines and reduce the burden of disease,” added Dr. Karen H. Møller, Senior Director of Diabetes Research.

What the patent actually covers (simplified)

  1. Molecular design – Insulin molecules that have specific amino‑acid substitutions at positions that control absorption and half‑life.
  2. Formulation – Pharmaceutical compositions (e.g., aqueous solutions, prefilled pens) that incorporate the analogs in a way that optimizes stability and delivery.
  3. Method claims – Ways to treat type 1 or type 2 diabetes with these analogs, including dosage regimens that achieve a therapeutic window with fewer hypoglycemic episodes.

The claims are written broadly, ensuring coverage of both the individual molecules and any derivative formulations. This means that competitors who develop similar analogs without the exact substitutions or delivery system are likely still infringing.

Why the press release matters to stakeholders

Stakeholder Why this matters
Patients & clinicians Signals upcoming availability of once‑daily/weekly insulin options that could simplify treatment regimens.
Investors Adds to Novo Nordisk’s portfolio of protected innovations, supporting long‑term revenue forecasts.
Competitors Highlights the company’s deepening IP protection, which may limit the market share for rival insulin analogs.
Regulators Provides evidence that Novo Nordisk has a robust pipeline for future drug approvals.

Quick take‑away

  • US 9,102,762 is a cornerstone patent that protects a family of insulin analogs and their delivery systems.
  • The press release announced the grant and framed it as a leap forward in diabetes care, emphasizing improved patient convenience and safety.
  • For patients, this patent translates into the promise of fewer injections and better glucose control. For Novo Nordisk, it secures a competitive edge in the insulin marketplace for at least the next decade.

Want to read the full text?



Other Questions About Novo :

novolog mix 70/30 flexpen price Novo rapid patent expire? Novo nordisk semaglutide patent status? Novo nordisk wegovy patent expiration date? Novo clonidine 0 025 mg? Novo nordisk ozempic list price 2023? Novo nordisk saxenda patent brazil legal challenges 2025?